Browsing Tag
Gilead Sciences
54 posts
Gilead Sciences (GILD) is buying Tubulis after Arcellx and Ouro. How aggressive is this deal spree getting?
Gilead is acquiring Tubulis for up to $5 billion to expand its ADC pipeline. Read what the deal means for oncology strategy, risk, and GILD stock.
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
Gilead Sciences bets $2.2bn on immune reset with Ouro Medicines BCMAxCD3 bispecific acquisition
Gilead Sciences agrees to acquire Ouro Medicines for up to $2.175bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Read the full strategic analysis.
Repare Therapeutics (NASDAQ: RPTX) investors back acquisition by nonprofit XenoTherapeutics; court approval pending
Repare shareholders approve Xeno acquisition; cash payout rises to $2.20 after Gilead deal. Find out what this means for biotech investors and rivals.
Gilead Sciences acquires RP-3467 from Repare Therapeutics to strengthen synthetic lethality pipeline
Gilead buys RP-3467 from Repare for up to $30M, boosting Repare’s shareholder payout ahead of its Xeno acquisition. Find out what this means for oncology.
Mastek (NSE: MASTEK) appoints Google executive Marc Berson to board as AI-first strategy enters next phase
Mastek appoints Google tech leader Marc Berson to U.S. board as part of its AI-first growth push. Find out what this means for its global enterprise strategy.
Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings
Yescarta shows durable survival and response benefits in second-line large B-cell lymphoma across transplant-eligible and ineligible patients. Read the latest trial update.
Gilead’s $21bn cancer gamble faces major blow as Trodelvy fails in key breast cancer trial
Gilead’s Trodelvy failed to meet the main goal in a Phase 3 breast cancer trial, raising new questions about its oncology growth strategy.
Is Arcus Biosciences (RCUS) the dark horse of cancer immunotherapy after 26.7-month survival data?
Arcus stock jumped after its domvanalimab-zimberelimab combo showed 26.7-month survival in gastric cancer. Find out what this means for its TIGIT pipeline.
AusperBio raises $63mn series B2 round to advance AHB-137 and expand global hepatitis B
AusperBio raises $63M Series B2 funding to advance AHB-137 pivotal trials, expand its Med-Oligo platform, and reshape the hepatitis B cure race.